Literature DB >> 21955628

Incidence of early allograft rejection after Descemet membrane endothelial keratoplasty.

Isabel Dapena1, Lisanne Ham, Magdaléna Netuková, Jacqueline van der Wees, Gerrit R J Melles.   

Abstract

PURPOSE: To report the incidence of early allograft rejection after Descemet membrane endothelial keratoplasty (DMEK), that is, transplantation of isolated Descemet membrane with its endothelium.
METHODS: The first series of 120 eyes of 105 patients operated on for Fuchs endothelial dystrophy or pseudophakic bullous keratopathy, with an average 2 years of follow-up after 9.0- to 10.0-mm-diameter DMEK, enrolled in our study.
RESULTS: During the entire study period, only 1 of the eyes showed any signs of a cellular immune response to the Descemet graft. A 76-year-old patient presented with discomfort, reduced visual acuity to counting fingers, corneal decompensation, and a Khodadoust line in the central cornea 4 months after (decentered) DMEK. Intensified topical corticoid therapy resulted in a complete visual recovery to 20/25 (0.8) within weeks.
CONCLUSIONS: A "classic" allograft rejection (with an appearance similar to that after penetrating keratoplasty) can occur after DMEK. However, compared with the earlier (endothelial) keratoplasty procedures, DMEK may be associated with a lower rejection rate of ≤ 1%, despite transplant diameters of ± 9.5 mm. The apparent immune tolerance in DMEK may result from either less "upregulation" or more "downregulation" of the immune system.

Entities:  

Mesh:

Year:  2011        PMID: 21955628     DOI: 10.1097/ICO.0b013e31820d8540

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  11 in total

1.  Outcomes of Descemet Membrane Endothelial Keratoplasty in Patients With Previous Glaucoma Surgery.

Authors:  Carolina Aravena; Fei Yu; Sophie X Deng
Journal:  Cornea       Date:  2017-03       Impact factor: 2.651

2.  Evolving Techniques in Corneal Transplantation.

Authors:  Grace E Boynton; Maria A Woodward
Journal:  Curr Surg Rep       Date:  2015-02-01

3.  Clinical results of non-Descemet stripping endothelial keratoplasty.

Authors:  Tao Zhang; Shao-Wei Li; Tie-Hong Chen; Jing-Liang He; Yan-Wei Kang; Fang-Qi Lyu; Jian-Hua Ning; Chang Liu
Journal:  Int J Ophthalmol       Date:  2017-02-18       Impact factor: 1.779

4.  Impact of Donor Age on Corneal Endothelium-Descemet Membrane Layer Scroll Formation.

Authors:  Adam Bennett; Shahira Mahmoud; Donna Drury; H Dwight Cavanagh; James P McCulley; W Matthew Petroll; V Vinod Mootha
Journal:  Eye Contact Lens       Date:  2015-07       Impact factor: 2.018

5.  Optical characteristics after Descemet membrane endothelial keratoplasty: 1-year results.

Authors:  Takahiko Hayashi; Akira Kobayashi; Hidenori Takahashi; Itaru Oyakawa; Naoko Kato; Takefumi Yamaguchi
Journal:  PLoS One       Date:  2020-10-14       Impact factor: 3.240

6.  Herpes Simplex Virus Endotheliitis following Descemet's Membrane Endothelial Keratoplasty.

Authors:  Siamak Zarei-Ghanavati; Reza Alizadeh; Sonia H Yoo
Journal:  J Ophthalmic Vis Res       Date:  2015 Apr-Jun

7.  Survey of Experts on Current Endothelial Keratoplasty Techniques.

Authors:  Winston Chamberlain; Ariana Austin; Mark Terry; Bennie H Jeng; Jennifer Rose-Nussbaumer
Journal:  J Clin Exp Ophthalmol       Date:  2016-10-27

Review 8.  Lamellar keratoplasty: a literature review.

Authors:  Ladan Espandar; Alan N Carlson
Journal:  J Ophthalmol       Date:  2013-10-07       Impact factor: 1.909

9.  Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction.

Authors:  Naoki Okumura; Yuji Sakamoto; Keita Fujii; Junji Kitano; Shinichiro Nakano; Yuki Tsujimoto; Shin-Ichiro Nakamura; Morio Ueno; Michio Hagiya; Junji Hamuro; Akifumi Matsuyama; Shingo Suzuki; Takashi Shiina; Shigeru Kinoshita; Noriko Koizumi
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

Review 10.  Fuchs endothelial corneal dystrophy: current perspectives.

Authors:  Gustavo Vedana; Guadalupe Villarreal; Albert S Jun
Journal:  Clin Ophthalmol       Date:  2016-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.